approval
saveSYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
community read0 votes
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025 · 342d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalMar 7, 2025 · 573d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 30, 2023 · 1067d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023 · 1199d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 20, 2023 · 1199d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalFeb 6, 2023 · 1333d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalMar 21, 2022 · 1655d ago
- approvalSYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021 · 1938d ago
same company · ±60 days · 6
- approvalSYNJARDY: JARDIANCE (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approval(empagliflozin + linagliptin + metformin hydrochloride) ER: TRIJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approval(empagliflozin + linagliptin): GLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approvalSYNJARDY: SYNJARDY (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approvalCYLTEZO: CYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 3, 2022
- approvalspesolimab: SPEVIGO (SPESOLIMAB-SBZO) — FDA approvalSep 1, 2022
comments(0)
5-min edit window · permanent after that